{
  "abstract": "Pulmonary function tests are essential diagnostic tools in respiratory medicine, with interpretation dependent on predicted normal values derived from population-based reference equations. Historically, these equations included race as a variable, based on the assumption that individuals from different racial backgrounds have innate physiological differences in lung function. However, this practice has come under increasing scrutiny, as emerging evidence shows that observed racial differences are not due to inherent anatomical variation, such as chest size or airway diameter, but rather reflect the cumulative impact of structural inequities, including limited access to clean air, nutritious food, quality healthcare and safe housing.1",
  "authors": [
    {
      "affiliations": [
        "Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia",
        "University of Novi Sad Faculty of Medicine, Novi Sad, Serbia"
      ],
      "name": "Marija Vukoja"
    }
  ],
  "title": "Who gets in? Rethinking clinical trial access in the era of race-neutral pulmonary function",
  "uid": "b2d6bfed-be31-5b95-a958-5e78f654e293"
}